Switch theme
Sign up to access all valuation multiples
Bioporto AS is an in-vitro diagnostic company. The company provides healthcare professionals in clinical and research settings with a range of diagnostic tests and antibodies. Its product portfolio consists of specialized monoclonal antibodies and antibody-based diagnostic assays, used in the treatment of critically ill patients. The company's products include the NGAL Test, ELISA kits, Antibodies, and Other products and licenses. Geographically, it derives a majority of its revenue from North America.
2000
31
LTM Revenue $6.5M
Last FY EBITDA -$10.7M
$93.1M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Bioporto has a last 12-month revenue (LTM) of $6.5M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Bioporto achieved revenue of $5.5M and an EBITDA of -$10.7M.
Bioporto expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Bioporto valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $6.5M | XXX | $5.5M | XXX | XXX | XXX |
| Gross Profit | $4.4M | XXX | $3.7M | XXX | XXX | XXX |
| Gross Margin | 68% | XXX | 68% | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$10.7M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -196% | XXX | XXX | XXX |
| EBIT | -$12.0M | XXX | -$11.4M | XXX | XXX | XXX |
| EBIT Margin | -186% | XXX | -208% | XXX | XXX | XXX |
| Net Profit | -$11.0M | XXX | -$10.3M | XXX | XXX | XXX |
| Net Margin | -170% | XXX | -188% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Bioporto's stock price is DKK 1 (or $0).
Bioporto has current market cap of DKK 641M (or $96.5M), and EV of DKK 618M (or $93.1M).
See Bioporto trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $93.1M | $96.5M | XXX | XXX | XXX | XXX | $-0.03 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Bioporto has market cap of $96.5M and EV of $93.1M.
Bioporto's trades at 17.1x EV/Revenue multiple, and -8.7x EV/EBITDA.
Equity research analysts estimate Bioporto's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Bioporto has a P/E ratio of -8.8x.
See valuation multiples for Bioporto and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $96.5M | XXX | $96.5M | XXX | XXX | XXX |
| EV (current) | $93.1M | XXX | $93.1M | XXX | XXX | XXX |
| EV/Revenue | 14.4x | XXX | 17.1x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -8.7x | XXX | XXX | XXX |
| EV/EBIT | -7.8x | XXX | -8.2x | XXX | XXX | XXX |
| EV/Gross Profit | 21.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | -8.8x | XXX | -9.4x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -7.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialBioporto's last 12 month revenue growth is 22%
Bioporto's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.5M for the same period.
Bioporto's rule of 40 is -165% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Bioporto's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Bioporto and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 22% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -196% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -165% | XXX | -174% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 83% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 93% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 276% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Australian Clinical Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Clarity Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| CurveBeam AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Cyclopharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Healius | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Bioporto acquired XXX companies to date.
Last acquisition by Bioporto was XXXXXXXX, XXXXX XXXXX XXXXXX . Bioporto acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Bioporto founded? | Bioporto was founded in 2000. |
| Where is Bioporto headquartered? | Bioporto is headquartered in Denmark. |
| How many employees does Bioporto have? | As of today, Bioporto has 31 employees. |
| Who is the CEO of Bioporto? | Bioporto's CEO is Mr. Peter Morch Eriksen. |
| Is Bioporto publicy listed? | Yes, Bioporto is a public company listed on CSE. |
| What is the stock symbol of Bioporto? | Bioporto trades under BIOPOR ticker. |
| When did Bioporto go public? | Bioporto went public in 1993. |
| Who are competitors of Bioporto? | Similar companies to Bioporto include e.g. Australian Clinical Labs, Clarity Pharmaceuticals, CurveBeam AI, Cyclopharm. |
| What is the current market cap of Bioporto? | Bioporto's current market cap is $96.5M |
| What is the current revenue of Bioporto? | Bioporto's last 12 months revenue is $6.5M. |
| What is the current revenue growth of Bioporto? | Bioporto revenue growth (NTM/LTM) is 22%. |
| What is the current EV/Revenue multiple of Bioporto? | Current revenue multiple of Bioporto is 14.4x. |
| Is Bioporto profitable? | Yes, Bioporto is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
